The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
Cinemark (CNK) – The movie theater operator’s stock gained 4.6% in premarket action after Morgan Stanley upgraded it to “overweight” from “equal-weight.” Morgan Stanley said the return of consumers to theaters represents a trend not reflected in the stock’s price.
We all know that CINE did not take this seriously at the time and that the judgement was ridiculous. Therefore the appeal will either go in favour of CINE or be a lower amount. The reason being is that the board are keeping the share low and suggesting that they are on the brink to influence the outcome, whether an agreed settlement or a better judgement. I see this as a great buying opportunity based on these facts. This could be a 10 bagger in 12 months but also could slump. Depends on your view.
Why did the shareholders ask for this to be removed.
Let’s assume it was Polygon, why would they do this.
Thoughts
1. They didn’t want their shareholding to dilute
2. They are building a stake for someone else and therefore want to keep equity levels stable.
3. They know a full JV take-over is coming and these resolutions would scupper that.
2 million people are still affected by Covid in the U.K. my wife used to run everyday, got as a fiddle, now she can’t walk up the stairs without needing to lie down. My point is if Synairgen prove this improves long Covid, this will be a game changer.
Whether news imminent or a longer term plan, this is really positive for holders. I would be looking at this if I was a major investor/investment institutions and be thinking what do they know to hold 27% of the company.
Hi due to personal circumstances had to sell at 271. I was absolutely gutted. So to see this at 220’s is ridiculous. I would be selling everything to buy more, but alas that’s why i had to sell in the first place.
Traders gone on the spike. Held well and now gradual rise. Let’s see what the presentation brings and additional PR. Whatever anyone thinks, today we are in much better shape than yesterday and have proved the test was the problem not the product.
Let’s see how the market reacts and also potential partners at the conference. Is this why Polygon have 25% of the company.
I don’t expect this to fly but the share price now has a more solid floor and should rise gradually.